Schedule-dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin.
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D003561:Cytarabine / Q000008:administration & dosage* / Q000627:therapeutic use; D003630:Daunorubicin / Q000008:administration & dosage* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D007939:Leukemia L1210 / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008811:Mice, Inbred DBA; D013997:Time Factors
D003561:Cytarabine; D003630:Daunorubicin